• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Evolus, Inc. - Common Stock (NQ:EOLS)

    7.660 -0.030 (-0.39%)
    Delayed Quote Updated: 9:34 AM EDT, Oct 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 11,753
    Open 7.720
    Bid (Size) 7.640 (200)
    Ask (Size) 7.680 (200)
    Prev. Close 7.690
    Today's Range 7.660 - 7.720
    52wk Range 3.860 - 9.310
    Shares Outstanding 54,576,156
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
    From Evolus
    Via Business Wire
    Evolus Inc (NASDAQ:EOLS) Passes Minervini Trend Template and High Growth Momentum Screen ↗
    Via Chartmill

    Performance

    YTD
    +14.0%
    +14.0%
    1 Month
    -15.6%
    -15.6%
    3 Month
    +11.0%
    +11.0%
    6 Month
    +90.1%
    +90.1%
    1 Year
    +24.6%
    +24.6%

    More News

    Read More
    News headline image
    Telix Appoints David Gill as Chair
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Evolus Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Evolus (NASDAQ:EOLS) Tops Q2 EPS Estimates and Raises Revenue Guidance, Shares Gain 5.7% ↗
    Via Chartmill
    Evolus Inc (NASDAQ:EOLS) Q1 2026 Earnings: Narrowed Loss and Positive EBITDA Drive After-Hours Rally ↗
    Via Chartmill
    Evolus Inc (NASDAQ:EOLS) Reports Q4 2025 Earnings Beat and Path to 2026 Profitability ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
    From Evolus
    Via Business Wire
    News headline image
    Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
    From Evolus
    Via Business Wire
    News headline image
    Evolus to Report Second Quarter Financial Results on August 5, 2026
    From Evolus
    Via Business Wire
    News headline image
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    News headline image
    Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
    From Evolus
    Via Business Wire
    News headline image
    Evolus to Participate in The Jefferies Global Healthcare Conference
    From Evolus
    Via Business Wire
    News headline image
    Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
    From Evolus
    Via Business Wire
    News headline image
    Evolus (EOLS) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    Topics World Trade
    News headline image
    Evolus (EOLS) Q2 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings World Trade
    News headline image
    Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
    From Evolus
    Via Business Wire
    News headline image
    Evolus to Report First Quarter Financial Results on May 4, 2026
    From Evolus
    Via Business Wire
    News headline image
    Telix Appoints David Gill as Non-Executive Director
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
    From Evolus
    Via Business Wire
    News headline image
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    News headline image
    Why Evolus Stock Soared Today ↗
    Via The Motley Fool
    What's going on in today's session ↗
    Via Chartmill
    Gapping stocks in Wednesday's session ↗
    Via Chartmill
    News headline image
    Evolus (EOLS) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings World Trade

    Frequently Asked Questions

    Is Evolus, Inc. - Common Stock publicly traded?
    Yes, Evolus, Inc. - Common Stock is publicly traded.
    What exchange does Evolus, Inc. - Common Stock trade on?
    Evolus, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Evolus, Inc. - Common Stock?
    The ticker symbol for Evolus, Inc. - Common Stock is EOLS on the Nasdaq Stock Market
    What is the current price of Evolus, Inc. - Common Stock?
    The current price of Evolus, Inc. - Common Stock is 7.660
    When was Evolus, Inc. - Common Stock last traded?
    The last trade of Evolus, Inc. - Common Stock was at 10/02/26 09:34 AM ET
    What is the market capitalization of Evolus, Inc. - Common Stock?
    The market capitalization of Evolus, Inc. - Common Stock is 418.05M
    How many shares of Evolus, Inc. - Common Stock are outstanding?
    Evolus, Inc. - Common Stock has 418M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.